GLOBE LIFE INC
For the period ended Dec 31, 2023. Filed Feb 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 28, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Restrictions Note 13—Shareholders' Equity
Restrictions: Restrictions exist on the flow of funds to Globe Life Inc. from its insurance subsidiaries. Statutory regulations require life insurance subsidiaries to maintain certain minimum amounts of capital and surplus. Dividends from insurance subsidiaries of Globe Life Inc. are restricted based on regulations by their states of domicile. Additionally, insurance company distributions are generally not permitted in excess of statutory surplus. Subsidiaries are also subject to certain minimum capital requirements. Subsidiaries of Globe Life paid cash dividends to the Parent Company in the amount of $460 million in 2023, $407 million in 2022, and $479 million in 2021. As of December 31, 2023, dividends from insurance subsidiaries to the Parent Company available to be paid in 2024 are limited to the amount of $466 million without regulatory approval, such that $1.2 billion was considered restricted net assets of the subsidiaries. Dividends exceeding these limitations may be available during the year pending regulatory approval. While there are no legal restrictions on the payment of dividends to shareholders from Globe Life's retained earnings, retained earnings as of December 31, 2023 were restricted by lenders’ covenants which require the Company to maintain and not distribute $4.3 billion from its total consolidated retained earnings of $7.5 billion.
Earnings per Share: A reconciliation of basic and diluted weighted-average shares outstanding used in the computation of basic and diluted earnings per share is as follows:
| Year Ended December 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| Basic weighted average shares outstanding | 95,098,474 | 97,927,770 | 102,069,781 |
| Weighted average dilutive options outstanding | 1,265,367 | 1,056,874 | 1,100,351 |
| Diluted weighted average shares outstanding | 96,363,841 | 98,984,644 | 103,170,132 |
| Antidilutive shares | 422,739 | 31,269 | 2,412,884 |
Antidilutive shares are excluded from the calculation of diluted earnings per share. All antidilutive shares noted above result from outstanding out of the money employee and Director stock options.
Note 14—Stock-Based Compensation
Globe Life's stock-based compensation consists of stock options, restricted stock, restricted stock units, and performance shares. Certain employees and members of the board of directors (directors) have been granted fixed equity options to buy shares of Globe Life stock at the market value of the stock on the date of grant, under the provisions of the Globe Life stock option plans. The options are exercisable during the period commencing from the date they vest until expiring according to the terms of the grant. Options generally expire the earlier of employee termination or option contract term, which are either seven-year orten-year terms. However, depending on the circumstances of termination, options may be exercised for a period of time following termination of employment or upon death or disability. Options generally vest in accordance with the following schedule:
| Shares vested by period | |||||||
|---|---|---|---|---|---|---|---|
| Contract Period | 6 Months | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | |
| Directors | 7 years | 100% | —% | —% | —% | —% | —% |
| Employees | 7 years | —% | —% | 50% | 50% | —% | —% |
| Employees | 10 years | —% | —% | 25% | 25% | 25% | 25% |
All employee options vest immediately upon retirement on or after the attainment of age 65, upon death, or disability. Globe Life generally issues shares for the exercise of stock options from treasury stock. The Company generally uses the proceeds from option exercises to buy shares of Globe Life common stock in the open market to reduce the dilution from option exercises.
An analysis of shares available for grant is as follows:
| Available for Grant | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| Balance at January 1, | 3,177,886 | 4,727,088 | 5,984,418 |
| Options expired and forfeited during year(1) | 122,962 | 13,405 | 5,304 |
| Performance shares expired and forfeited during year(2) | 39,060 | 23,250 | 34,255 |
| Restricted stock units expired and forfeited during the year(2) | 12,513 | — | — |
| Options granted during year(1) | (422,501) | (1,105,180) | (1,091,495) |
| Restricted stock, restricted stock units, and performance shares granted(2) | (598,604) | (480,677) | (205,394) |
| Balance at December 31, | 2,331,316 | 3,177,886 | 4,727,088 |
(1)Plan allows for grant of options such that each grant reduces shares available for grant in a range from 0.85 share to 1.0 share.
(2)Plan allows for grant of restricted stock, restricted stock units and performance shares such that each stock grant reduces shares available for grant in a range from 3.10 shares to 3.88 shares.
A summary of stock compensation activity for each of the three years ended December 31, 2023 is presented below:
| 2023 | 2022 | 2021 | |
|---|---|---|---|
| Stock-based compensation expense recognized(1) | $30,736 | $35,650 | $30,272 |
| Tax benefit recognized | 11,178 | 12,738 | 11,954 |
(1)No stock-based compensation expense was capitalized in any period in accordance with applicable GAAP.
Additional stock compensation information is as follows at December 31:
| 2023 | 2022 | |
|---|---|---|
| Unrecognized compensation(1) | $36,599 | $33,977 |
| Weighted average period of expected recognition (in years)(1) | 0.53 | 0.56 |
(1)Includes stock options, restricted stock units and performance shares.
No equity awards were cash settled during the three years ended December 31, 2023.
Options: The following table summarizes information about stock options outstanding at December 31, 2023.
| Options Outstanding · Options Exercisable | |||||
|---|---|---|---|---|---|
| Range ofExercise Prices | NumberOutstanding | Weighted-AverageRemainingContractualLife (Years) | Weighted-AverageExercisePrice | NumberExercisable | Weighted-AverageExercisePrice |
| $50.64 - $82.56 | 1,210,102 | 2.25 | $78.28 | 1,210,102 | $78.28 |
| 87.60 - 98.32 | 1,908,002 | 3.33 | 93.98 | 1,435,140 | 92.55 |
| 100.74 | 1,039,117 | 3.09 | 100.74 | 1,039,117 | 100.74 |
| 103.23 - 120.49 | 1,783,099 | 5.35 | 108.04 | 318,669 | 103.46 |
| $50.64 - $120.49 | 5,940,320 | 3.68 | $96.19 | 4,003,028 | $91.23 |
An analysis of option activity for each of the three years ended December 31, 2023, is as follows:
| 2023 | 2022 | 2021 | ||||
|---|---|---|---|---|---|---|
| Options | Weighted-AverageExercise Price | Options | Weighted-AverageExercise Price | Options | Weighted-AverageExercise Price | |
| Outstanding—beginning of year | 6,962,374 | $91.73 | 7,197,662 | $85.11 | 7,111,231 | $78.28 |
| Granted: | ||||||
| 7-year term | 497,060 | 120.49 | 1,300,211 | 103.20 | 1,284,112 | 98.28 |
| Exercised | (1,375,313) | 82.95 | (1,519,728) | 70.14 | (1,191,704) | 58.59 |
| Expired and forfeited | (143,801) | 90.92 | (15,771) | 96.54 | (5,977) | 74.15 |
| Outstanding—end of year | 5,940,320 | $96.19 | 6,962,374 | $91.73 | 7,197,662 | $85.11 |
| Exercisable at end of year | 4,003,028 | $91.23 | 3,666,871 | $84.00 | 3,659,755 | $75.55 |
Additional information about Globe Life's stock option activity as of December 31, 2023 and 2022 is as follows:
| 2023 | 2022 | |
|---|---|---|
| Outstanding options: | ||
| Weighted-average remaining contractual term (in years) | 3.68 | 4.08 |
| Aggregate intrinsic value | $151,685 | $200,681 |
| Exercisable options: | ||
| Weighted-average remaining contractual term (in years) | 3.01 | 3.01 |
| Aggregate intrinsic value | $122,052 | $134,033 |
Selected stock option activity for the three years ended December 31, 2023, is presented below:
| 2023 | 2022 | 2021 | |
|---|---|---|---|
| Weighted-average grant-date fair value of options granted (per share) | $32.25 | $22.03 | $18.01 |
| Intrinsic value of options exercised | 49,163 | 58,201 | 50,641 |
| Cash received from options exercised | 114,080 | 106,592 | 69,826 |
| Actual tax benefit received | 9,379 | 11,907 | 10,545 |
Additional information concerning Globe Life's unvested options is as follows at December 31:
| 2023 | 2022 | |
|---|---|---|
| Number of shares outstanding | 1,937,292 | 3,295,503 |
| Weighted-average exercise price (per share) | $106.42 | $100.33 |
| Weighted-average remaining contractual term (in years) | 5.05 | 5.26 |
| Aggregate intrinsic value | $29,634 | $66,647 |
Globe Life expects that substantially all unvested options will vest.
Restricted Stock: Restricted stock grants consist of time-vested grants, restricted stock units, and performance shares. Time-vested restricted stock is available to directors and vests oversix months. The directors' restricted stock units vest oversix months and are converted to shares upon their retirement from the Board. Employees' restricted stock units vest and become non-forfeitable on the vesting date (generally three years from the grant date) or upon meeting certain retirement criteria, or in the event of death or disability. Director restricted stock and restricted stock units are generally granted on the first business day of the calendar year. Performance shares are granted to a limited number of senior executives. Performance shares have athree-year performance period and are not settled in shares until the certification of thethree-year performance period. While the grant specifies a stated target number of shares, the determination of the actual settlement in shares will be based on the achievement of certain performance objectives of Globe Life over thethree-year performance period. Certain executive restricted stock and performance share grants contain terms related to age that could accelerate vesting.
Following are the restricted stock units outstanding for each of the three years ended December 31, 2023.
| Year of grants | Outstanding as of year end |
|---|---|
| 2021 | 84,426 |
| 2022 | 93,381 |
| 2023 | 163,108 |
Below is the final determination of the performance share grants in 2019 to 2021:
| Year of grants | Final settlement of shares | Final settlement date |
|---|---|---|
| 2019 | 66,751 | February 23, 2022 |
| 2020 | 84,298 | February 22, 2023 |
| 2021 | 143,211 | February 28, 2024 |
For the 2022 and 2023 performance share grants, actual shares that could be distributed range from 0 to 220 thousand for the 2022 grants and 0 to 122 thousand shares for the 2023 grants.
A summary of restricted stock grants for each of the years in the three-year period ended December 31, 2023, is presented in the table below.
| 2023 | 2022 | 2021 | |
|---|---|---|---|
| Directors restricted stock: | |||
| Shares | 7,110 | 10,746 | 10,031 |
| Price per share | $119.59 | $94.94 | $92.40 |
| Aggregate value | $850 | $1,020 | $927 |
| Percent vested | 100% | 100% | 97% |
| Directors restricted stock units (including dividend equivalents): | |||
| Shares | 9,479 | 8,956 | 7,258 |
| Price per share | $117.73 | $95.62 | $92.60 |
| Aggregate value | $1,116 | $856 | $672 |
| Percent vested | 100% | 100% | 96% |
| Employees restricted stock units: | |||
| Shares | 96,975 | — | — |
| Price per share | $120.18 | $— | $— |
| Aggregate value | $11,654 | $— | $— |
| Percent vested | —% | —% | —% |
| Performance shares: | |||
| Target shares | 81,300 | 146,500 | 139,500 |
| Target price per share | $120.49 | $103.23 | $98.32 |
| Aggregate value | $9,796 | $15,123 | $13,716 |
| Percent vested | —% | —% | —% |
Time-vested restricted stockholders are entitled to dividend payments on the unvested stock. Director restricted stock unit holders are entitled to dividend equivalents. These equivalents are granted in the form of additional restricted stock units and vest immediately upon grant. Dividend equivalents are applicable only to directors' restricted stock units. Performance shares held by employees are not entitled to dividend equivalents and are not entitled to dividend payments until the shares are vested and settled.
An analysis of nonvested restricted stock is as follows:
| ExecutivePerformanceShares | DirectorsRestrictedStock | DirectorsRestrictedStockUnits | EmployeesRestrictedStockUnits | Total | |
|---|---|---|---|---|---|
| 2021: | |||||
| Balance at December 31, 2020 | 518,976 | — | — | — | 518,976 |
| Grants | 139,500 | 10,031 | 7,258 | — | 156,789 |
| Additional performance shares(1) | (94,883) | — | — | — | (94,883) |
| Restriction lapses | (210,155) | (9,742) | (6,969) | — | (226,866) |
| Forfeitures | (11,050) | — | — | — | (11,050) |
| Balance at December 31, 2021 | 342,388 | 289 | 289 | — | 342,966 |
| 2022: | |||||
| Grants | 146,500 | 10,746 | 8,956 | — | 166,202 |
| Additional performance shares(1) | (16,102) | — | — | — | (16,102) |
| Restriction lapses | (66,751) | (11,035) | (9,245) | — | (87,031) |
| Forfeitures | (7,500) | — | — | — | (7,500) |
| Balance at December 31, 2022 | 398,535 | — | — | — | 398,535 |
| 2023: | |||||
| Grants | 81,300 | 7,110 | 9,479 | 96,975 | 194,864 |
| Additional performance shares(1) | (28,857) | — | — | — | (28,857) |
| Restriction lapses | (84,298) | (7,110) | (9,479) | — | (100,887) |
| Forfeitures | (12,600) | — | — | (4,410) | (17,010) |
| Balance at December 31, 2023 | 354,080 | — | — | 92,565 | 446,645 |
(1)Estimated additional (reduced) share grants expected due to achievement of performance criteria.
An analysis of the weighted-average grant-date fair values per share of nonvested restricted stock is as follows for the year 2023:
| Executive Performance Shares | Directors Restricted Stock | Directors Restricted Stock Units | EmployeesRestrictedStockUnits | |
|---|---|---|---|---|
| Grant-date fair value per share at January 1, 2023 | $100.68 | $— | $— | $— |
| Grants | 120.49 | 119.59 | 117.92 | 120.18 |
| Estimated additional performance shares | (99.81) | — | — | — |
| Restriction lapses | (100.74) | (119.59) | (117.92) | — |
| Forfeitures | (100.74) | — | — | (120.49) |
| Grant-date fair value per share at December 31, 2023 | 105.28 | — | — | 120.16 |
Note 15—Business Segments
Globe Life is organized into four segments: life insurance, supplemental health insurance, annuities, and investments. In addition, other expenses not included in these segments are reported in "Corporate & Other."
Globe Life's reportable insurance segments are based on the insurance product lines it markets and administers: life insurance, supplemental health insurance, and annuities. These major product lines are set out as reportable segments because of the common characteristics of products within these categories, comparability of margins, and the similarity in regulatory environment and management techniques. There is also an investment segment that manages the investment portfolio and cash flow for the insurance segments and the corporate function, which has been retrospectively adjusted to exclude the interest on deferred acquisition costs due to the adoption of ASU 2018-12 and the interest on debt. The Company's chief operating decision makers evaluate the overall performance of the operations of the Company in accordance with these segments.
Life insurance products marketed by Globe Life include traditional whole life and term life insurance. An immaterial amount of annuities sold as companion products are included in the life segment. Health insurance products are generally guaranteed renewable and include Medicare Supplement, cancer, critical illness, accident, and other limited-benefit supplemental hospital and surgical products. Annuities include fixed-benefit contracts.
The following tables present segment premium revenue by each of Globe Life's distribution channels.
Premium Income by Distribution Channel
| Life | Health | Annuity | Total | |||||
|---|---|---|---|---|---|---|---|---|
| Distribution Channel | Amount | % ofTotal | Amount | % ofTotal | Amount | % ofTotal | Amount | % ofTotal |
| American Income | $1,588,702 | 51 | $120,332 | 9 | $— | — | $1,709,034 | 38 |
| Direct to Consumer | 991,406 | 32 | 68,575 | 5 | — | — | 1,059,981 | 24 |
| Liberty National | 349,736 | 11 | 187,934 | 14 | — | — | 537,670 | 12 |
| United American | 7,311 | — | 545,723 | 42 | — | — | 553,034 | 13 |
| Family Heritage | 6,134 | — | 396,209 | 30 | — | — | 402,343 | 9 |
| Other | 193,955 | 6 | — | — | — | — | 193,955 | 4 |
| $3,137,244 | 100 | $1,318,773 | 100 | $— | — | $4,456,017 | 100 | |
| Life | Health | Annuity | Total | |||||
|---|---|---|---|---|---|---|---|---|
| Distribution Channel | Amount | % ofTotal | Amount | % ofTotal | Amount | % ofTotal | Amount | % ofTotal |
| American Income | $1,505,034 | 50 | $117,353 | 9 | $— | — | $1,622,387 | 38 |
| Direct to Consumer | 985,488 | 33 | 71,129 | 5 | — | — | 1,056,617 | 24 |
| Liberty National | 327,469 | 11 | 187,241 | 15 | — | — | 514,710 | 12 |
| United American | 7,966 | — | 539,874 | 42 | 1 | 100 | 547,841 | 13 |
| Family Heritage | 5,586 | — | 366,820 | 29 | — | — | 372,406 | 9 |
| Other | 196,281 | 6 | — | — | — | — | 196,281 | 4 |
| $3,027,824 | 100 | $1,282,417 | 100 | $1 | 100 | $4,310,242 | 100 | |
| Life | Health | Annuity | Total | |||||
|---|---|---|---|---|---|---|---|---|
| Distribution Channel | Amount | % ofTotal | Amount | % ofTotal | Amount | % ofTotal | Amount | % ofTotal |
| American Income | $1,401,898 | 48 | $114,742 | 9 | $— | — | $1,516,640 | 37 |
| Direct to Consumer | 968,365 | 34 | 73,976 | 6 | — | — | 1,042,341 | 25 |
| Liberty National | 311,200 | 11 | 187,669 | 16 | — | — | 498,869 | 12 |
| United American | 8,892 | — | 480,656 | 40 | 1 | 100 | 489,549 | 12 |
| Family Heritage | 4,957 | — | 343,839 | 29 | — | — | 348,796 | 9 |
| Other | 198,618 | 7 | — | — | — | — | 198,618 | 5 |
| $2,893,930 | 100 | $1,200,882 | 100 | $1 | 100 | $4,094,813 | 100 | |
Due to the nature of the life insurance industry, Globe Life has no individual or group which would be considered a major customer. Substantially all of Globe Life's business is conducted in the United States.
The measure of profitability established by the chief operating decision makers for the insurance segments is underwriting margin before other income and administrative expenses, in accordance with the manner in which the segments are managed. It essentially represents gross profit margin on insurance products before insurance administrative expenses and consists primarily of premium less net policy benefits, acquisition expenses, and commissions. Required interest on policy liabilities is reflected as a component of the Investment segment (rather than as a component of underwriting margin in the insurance and annuity segments) in order to match this cost with the investment income earned on the assets supporting the policy liabilities.
The measure of profitability for the Investment segment is excess investment income, representing the income earned on the investment portfolio in excess of policy requirements. During the implementation of ASU 2018-12, the Company reviewed its segment disclosures and modified the measure of profitability of our Investment Segment due to the adoption impact of the standard and to align more appropriately with how we view and measure this segment. As of January 1, 2023, this measure was retrospectively adjusted to exclude the interest on deferred acquisition costs due to the adoption of ASU 2018-12 and the interest expense on debt. Other than the above-mentioned interest allocations, no other intersegment revenues or expenses are recognized. Expenses directly attributable to corporate operations are included in the “Corporate & Other” category. Stock-based compensation expense is considered a corporate expense by Globe Life management and is included in this category. All other unallocated revenues and expenses on a pretax basis, including insurance administrative expense and interest on debt, are also included in the “Corporate & Other” segment category.
Globe Life holds a sizable investment portfolio to support its insurance liabilities, the yield from which is used to offset policy benefit, acquisition, administrative, and tax expenses. This yield or investment income is taken into account when establishing premium rates and profitability expectations for its insurance products. From time to time, investments are sold or called, or experience a credit loss event, each of which are reflected by the Company as realized gain (loss)—investments. These gains or losses generally occur as a result of disposition due to issuer calls, compliance with Company investment policies, or other reasons often beyond management’s control. Unlike investment income, realized gains and losses are incidental to insurance operations, and only overall yields are considered when setting premium rates or insurance product profitability expectations. While these gains and losses are not relevant to segment profitability or core operating results, they can have a material positive or negative result on net income. For these reasons, management removes realized investment gains and losses when it views its segment operations.
Management also removes non-operating items unrelated to the Company's core insurance activities when evaluating those results. Therefore, these items are excluded in its presentation of segment results because accounting guidance requires that operating segment results be presented as management views its business. With the exception of the administrative settlements, all of these items are included in “Other operating expense” in the Consolidated Statements of Operations for the appropriate year. See additional detail below in the tables.
The following tables set forth a reconciliation of Globe Life's revenues and operations by segment to its major income statement line items. See Note—1 Significant Accounting Policies for additional information concerning reconciling items of segment profits to pretax income.
| Year Ended December 31, 2023 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Life · Health · Annuity · Investment · Corporate & Other · Adjustments · Consolidated | |||||||||
| Revenue: | |||||||||
| Premium | $3,137,244 | $1,318,773 | $— | $— | $— | $— | $4,456,017 | ||
| Net investment income | — | — | — | 1,056,884 | — | — | 1,056,884 | ||
| Other income | — | — | — | — | 308 | — | 308 | ||
| Total revenue | 3,137,244 | 1,318,773 | — | 1,056,884 | 308 | — | 5,513,209 | ||
| Expenses: | |||||||||
| Policy obligations | 2,050,789 | 776,362 | 28,039 | 9,061 | — | — | 2,864,251 | ||
| Required interest on reserves | (772,701) | (106,516) | (38,224) | 917,441 | — | — | — | ||
| Required interest on DAC | — | — | — | — | — | — | — | ||
| Amortization of acquisition costs | 327,426 | 50,598 | 1,676 | — | — | — | 379,700 | ||
| Commissions, premium taxes, and non-deferred acquisition costs | 338,758 | 220,392 | 17 | — | — | — | 559,167 | ||
| Insurance administrative expense(1) | — | — | — | — | 301,161 | 900 | (2) | 302,061 | |
| Parent expense | — | — | — | — | 10,866 | 4,170 | (3) | 15,036 | |
| Stock-based compensation expense | — | — | — | — | 30,736 | — | 30,736 | ||
| Interest expense | — | — | — | — | 102,316 | — | 102,316 | ||
| Total expenses | 1,944,272 | 940,836 | (8,492) | 926,502 | 445,079 | 5,070 | 4,253,267 | ||
| Subtotal | 1,192,972 | 377,937 | 8,492 | 130,382 | (444,771) | (5,070) | 1,259,942 | ||
| Non-operating items | — | — | — | — | — | 5,070 | (2,3) | 5,070 | |
| Measure of segment profitability (pretax) | $1,192,972 | $377,937 | $8,492 | $130,382 | $(444,771) | $— | 1,265,012 | ||
| Realized gain (loss)—investments | (65,676) | ||||||||
| Legal proceedings | (900) | ||||||||
| Non-operating expenses | (4,170) | ||||||||
| Income before income taxes per Consolidated Statements of Operations | $1,194,266 | ||||||||
(2)Legal proceedings
(3)Non-operating expenses.
| Year Ended December 31, 2022 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Life · Health · Annuity · Investment · Corporate & Other · Adjustments · Consolidated | |||||||||
| Revenue: | |||||||||
| Premium | $3,027,824 | $1,282,417 | $1 | $— | $— | $— | $4,310,242 | ||
| Net investment income | — | — | — | 991,800 | — | — | 991,800 | ||
| Other income | — | — | — | — | 1,246 | — | 1,246 | ||
| Total revenue | 3,027,824 | 1,282,417 | 1 | 991,800 | 1,246 | — | 5,303,288 | ||
| Expenses: | |||||||||
| Policy obligations | 2,035,693 | 752,866 | 32,503 | 4,372 | — | — | 2,825,434 | ||
| Required interest on reserves | (735,688) | (102,315) | (44,836) | 882,839 | — | — | — | ||
| Amortization of acquisition costs | 298,841 | 48,185 | 1,798 | — | — | — | 348,824 | ||
| Commissions, premium taxes, and non-deferred acquisition costs | 299,453 | 206,544 | 25 | — | — | — | 506,022 | ||
| Insurance administrative expense(1) | — | — | — | — | 299,341 | 8,175 | (2,3) | 307,516 | |
| Parent expense | — | — | — | — | 11,156 | (368) | (3) | 10,788 | |
| Stock-based compensation expense | — | — | — | — | 35,650 | — | 35,650 | ||
| Interest expense | — | — | — | — | 90,395 | — | 90,395 | ||
| Total expenses | 1,898,299 | 905,280 | (10,510) | 887,211 | 436,542 | 7,807 | 4,124,629 | ||
| Subtotal | 1,129,525 | 377,137 | 10,511 | 104,589 | (435,296) | (7,807) | 1,178,659 | ||
| Non-operating items | — | — | — | — | — | 7,807 | (2,3) | 7,807 | |
| Measure of segment profitability (pretax) | $1,129,525 | $377,137 | $10,511 | $104,589 | $(435,296) | $— | 1,186,466 | ||
| Realized gain (loss)—investments | (76,548) | ||||||||
| Legal proceedings | (2,496) | ||||||||
| Non-operating expenses | (5,311) | ||||||||
| Income before income taxes per Consolidated Statements of Operations | $1,102,111 | ||||||||
(2)Legal proceedings.
(3)Non-operating expenses.
| Year Ended December 31, 2021 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Life · Health · Annuity · Investment · Corporate & Other · Adjustments · Consolidated | |||||||||||
| Revenue: | |||||||||||
| Premium | $2,893,930 | $1,200,882 | $1 | $— | $— | $— | $4,094,813 | ||||
| Net investment income | — | — | — | 956,690 | — | — | 956,690 | ||||
| Other income | — | — | — | — | 1,216 | — | 1,216 | ||||
| Total revenue | 2,893,930 | 1,200,882 | 1 | 956,690 | 1,216 | — | 5,052,719 | ||||
| Expenses: | |||||||||||
| Policy obligations | 1,897,194 | 721,309 | 34,975 | 4,243 | — | 1,325 | (2) | 2,659,046 | |||
| Required interest on reserves | (710,301) | (98,477) | (46,695) | 855,473 | — | — | — | ||||
| Required interest on DAC | — | — | — | — | — | — | — | ||||
| Amortization of acquisition costs | 270,924 | 44,824 | 1,868 | — | — | — | 317,616 | ||||
| Commissions, premium taxes, and non-deferred acquisition costs | 274,475 | 180,748 | 27 | — | — | — | 455,250 | ||||
| Insurance administrative expense(1) | — | — | — | — | 271,631 | 10,398 | (3,4) | 282,029 | |||
| Parent expense | — | — | — | — | 9,553 | 175 | (4) | 9,728 | |||
| Stock-based compensation expense | — | — | — | — | 30,272 | — | 30,272 | ||||
| Interest expense | — | — | — | 83,486 | — | 83,486 | |||||
| Total expenses | 1,732,292 | 848,404 | (9,825) | 859,716 | 394,942 | 11,898 | 3,837,427 | ||||
| Subtotal | 1,161,638 | 352,478 | 9,826 | 96,974 | (393,726) | (11,898) | 1,215,292 | ||||
| Non-operating items | — | — | — | — | — | 11,898 | (2,3,4) | 11,898 | |||
| Measure of segment profitability (pretax) | $1,161,638 | $352,478 | $9,826 | $96,974 | $(393,726) | $— | 1,227,190 | ||||
| Realized gain (loss)—investments | 68,633 | ||||||||||
| Realized loss—redemption of debt | (9,314) | ||||||||||
| Administrative settlements | (1,325) | ||||||||||
| Legal proceedings | (8,139) | ||||||||||
| Non-operating expenses | (2,434) | ||||||||||
| Income before income taxes per Consolidated Statements of Operations | $1,274,611 | ||||||||||
(2)Administrative settlements.
(3)Legal proceedings.
(4)Non-operating expenses.
Assets for each segment are reported based on a specific identification basis. The insurance segments’ assets contain DAC. The investment segment includes the investment portfolio, cash, and accrued investment income. Goodwill is assigned to the insurance segments at the time of purchase. All other assets are included in the Corporate & Other category. The tables below reconcile segment assets to total assets as reported on the Consolidated Balance Sheets.
Assets by Segment
| At December 31, 2023 | ||||||
|---|---|---|---|---|---|---|
| Life | Health | Annuity | Investment | Corporate & Other | Consolidated | |
| Cash and invested assets | $— | $— | $— | $19,827,199 | $— | $19,827,199 |
| Accrued investment income | — | — | — | 270,396 | — | 270,396 |
| Deferred acquisition costs | 5,271,775 | 734,735 | 2,967 | — | — | 6,009,477 |
| Goodwill | 309,609 | 172,182 | — | — | — | 481,791 |
| Other assets | — | — | — | — | 1,462,636 | 1,462,636 |
| Total assets | $5,581,384 | $906,917 | $2,967 | $20,097,595 | $1,462,636 | $28,051,499 |
| At December 31, 2022 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Life · Health · Annuity · Investment · Corporate & Other · Consolidated | |||||||||
| Cash and invested assets | $— | $— | $— | $18,300,927 | $— | $18,300,927 | |||
| Accrued investment income | — | — | — | 259,581 | — | 259,581 | |||
| Deferred acquisition costs | 4,844,291 | 686,763 | 4,643 | — | — | 5,535,697 | |||
| Goodwill | 309,609 | 172,182 | — | — | 481,791 | ||||
| Other assets | — | — | — | — | 1,408,801 | 1,408,801 | |||
| Total assets | $5,153,900 | $858,945 | $4,643 | $18,560,508 | $1,408,801 | $25,986,797 | |||
Liabilities for each segment are reported also on a specific identification basis similar to the assets. The insurance segments' liabilities contain future policy benefits, unearned and advance premiums, and policy claims and other benefits payable. Other policyholders' funds are included in Other as well as current and deferred income taxes payable. Debt represents both short and long-term. The tables below reconcile segment liabilities to total liabilities as reported on the Consolidated Balance Sheets.
Liabilities by Segment
| At December 31, 2023 | ||||||
|---|---|---|---|---|---|---|
| Life | Health | Annuity | Investment | Corporate & Other | Consolidated | |
| Future policy benefits | $16,304,797 | $2,382,517 | $773,039 | $— | $— | $19,460,353 |
| Unearned and advance premiums | 196,630 | 57,937 | — | — | — | 254,567 |
| Policy claims and other benefits payable | 320,066 | 194,809 | — | — | — | 514,875 |
| Debt | — | — | — | 2,115,672 | — | 2,115,672 |
| Other | 98,958 | — | — | 138,000 | 982,271 | 1,219,229 |
| Total liabilities | $16,920,451 | $2,635,263 | $773,039 | $2,253,672 | $982,271 | $23,564,696 |
| At December 31, 2022 | ||||||
|---|---|---|---|---|---|---|
| Life | Health | Annuity | Investment | Corporate & Other | Consolidated | |
| Future policy benefits | $14,936,157 | $2,206,866 | $954,318 | $— | $— | $18,097,341 |
| Unearned and advance premiums | 196,263 | 57,097 | — | — | — | 253,360 |
| Policy claims and other benefits payable | 325,070 | 184,286 | — | — | — | 509,356 |
| Debt | — | — | — | 2,077,055 | — | 2,077,055 |
| Other | — | — | — | 23,000 | 1,077,108 | 1,100,108 |
| Total liabilities | $15,457,490 | $2,448,249 | $954,318 | $2,100,055 | $1,077,108 | $22,037,220 |
Note 16—Selected Quarterly Data (Unaudited)
The following is an unaudited summary of quarterly results for the two years ended December 31, 2023. The information includes all adjustments (consisting of normal accruals), which management considers necessary for a fair presentation of the results of operations for these periods. In addition, the figures below have been retrospectively adjusted due to the impacts of ASU 2018-12. See Note 1—Significant Accounting Policies for additional information regarding the impact of the adoption.
| Three Months Ended | ||||
|---|---|---|---|---|
| March 31, | June 30, | September 30, | December 31, | |
| 2023: | ||||
| Total assets | $26,922,329 | $26,769,793 | $26,223,345 | $28,051,499 |
| Total liabilities | 23,076,038 | 22,789,487 | 21,600,214 | 23,564,696 |
| Premium income | 1,095,090 | $1,110,920 | $1,119,335 | $1,130,672 |
| Net investment income | 257,105 | 261,244 | 266,926 | 271,609 |
| Realized gains (losses) | (30,927) | (45,843) | (2,193) | 13,287 |
| Total revenue | 1,321,318 | 1,326,406 | 1,384,118 | 1,415,691 |
| Policyholder benefits | 707,927 | 717,510 | 719,044 | 719,770 |
| Amortization of deferred acquisition costs | 92,322 | 94,080 | 95,757 | 97,541 |
| Pretax income | 274,234 | 264,506 | 318,815 | 336,711 |
| Net income | 223,610 | 215,260 | 257,083 | 274,802 |
| Basic net income per common share | 2.32 | 2.26 | 2.72 | 2.92 |
| Diluted net income per common share | 2.28 | 2.24 | 2.68 | 2.88 |
| Three Months Ended | ||||
|---|---|---|---|---|
| March 31, | June 30, | September 30, | December 31, | |
| 2022: | ||||
| Total assets | $28,215,723 | $26,424,294 | $25,248,899 | $25,986,797 |
| Total liabilities | 25,671,448 | 23,203,991 | 21,638,930 | 22,037,220 |
| Premium income | 1,064,812 | 1,077,199 | 1,079,282 | 1,088,949 |
| Net investment income | 244,894 | 244,712 | 246,711 | 255,483 |
| Realized gains (losses) | (7,244) | (30,446) | (29,155) | (9,703) |
| Total revenue | 1,302,626 | 1,291,764 | 1,297,237 | 1,335,113 |
| Policyholder benefits | 694,149 | 691,431 | 737,576 | 702,278 |
| Amortization of deferred acquisition costs | 84,496 | 86,185 | 88,012 | 90,131 |
| Pretax income | 294,176 | 276,449 | 234,776 | 296,710 |
| Net income | 237,484 | 223,973 | 190,586 | 242,343 |
| Basic net income per common share | 2.39 | 2.28 | 1.96 | 2.50 |
| Diluted net income per common share | 2.37 | 2.26 | 1.94 | 2.46 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.